Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to ...

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.

In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...

Immune-mediated diseases specialist Alumis has announced positive top-line results from its Phase III ONWARD1 and ONWARD2 ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and greater patient access to advanced therapies. The shift from conventional ...

Arrowhead Pharmaceuticals disclosed that its gene-silencing candidates helped people with obesity lose fat, very early ...

Australians living with a range of debilitating conditions including juvenile arthritis, rare liver disease and multiple ...

Eli Lilly has dominated headlines in recent months, recently taking the crown as the most valuable company in the biopharma ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the pricing of an ...

Betterguards, a global leader in sports protection technology, today announced the expansion of its product availability to Canada. While Betterguards' products have been adopted by professional ...